Skip to main content
Premium Trial:

Request an Annual Quote

Evotec, Takeda Pharmaceuticals Partner on RNA-Targeting Drug Development

NEW YORK — German drug discovery and development firm Evotec said on Monday that it has signed an agreed to develop RNA-targeting small molecule drugs in partnership with Takeda Pharmaceuticals.

Under the terms of the deal, the companies will jointly identify and develop the drugs against targets that fit within Takeda's disease areas of focus.

They will use Evotec's RNA targeting platform to identify RNA sequences that are amenable to small molecule ligands. The platform combines established drug discovery methods with new technologies such as third-generation sequencing and sequencing-based RNA structure elucidation.

Evotec stands to receive undisclosed research funding from Takeda, as well as discovery, pre-clinical, clinical, commercial, and sales milestone payments of up to $160 million per drug program. Evotec is also eligible for royalties on the sale of products resulting from the alliance.

Additional terms were not disclosed.

Last year, Evotec and Tokyo-based Takeda forged a multi-year partnership around gene therapy research.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.